Your browser doesn't support javascript.
loading
The prognostic utility of 18F-FDG PET parameters in lymphoma patients under CAR-T-cell therapy: a systematic review and meta-analysis.
Al-Ibraheem, Akram; Abdlkadir, Ahmed Saad; Al-Adhami, Dhuha Ali; Sathekge, Mike; Bom, Henry Hee-Seung; Ma'koseh, Mohammad; Mansour, Asem; Abdel-Razeq, Hikmat; Al-Rabi, Kamal; Estrada-Lobato, Enrique; Al-Hussaini, Maysaa; Matalka, Ismail; Abdel Rahman, Zaid; Fanti, Stephano.
Afiliación
  • Al-Ibraheem A; Department of Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC), Amman, Jordan.
  • Abdlkadir AS; School of Medicine, The University of Jordan, Amman, Jordan.
  • Al-Adhami DA; Department of Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC), Amman, Jordan.
  • Sathekge M; Department of Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC), Amman, Jordan.
  • Bom HH; Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Pretoria, South Africa.
  • Ma'koseh M; Nuclear Medicine Research Infrastructure (NuMeRI), Steve Biko Academic Hospital, Pretoria, South Africa.
  • Mansour A; Department of Nuclear Medicine, Steve Biko Academic Hospital, Pretoria, South Africa.
  • Abdel-Razeq H; Department of Nuclear Medicine, Chonnam National University Medical School (CNUMS) and Hospital, Gwangju, Republic of Korea.
  • Al-Rabi K; Department of Medicine, King Hussein Cancer Center (KHCC), Amman, Jordan.
  • Estrada-Lobato E; Department of Diagnostic Radiology, King Hussein Cancer Center (KHCC), Amman, Jordan.
  • Al-Hussaini M; Department of Medicine, King Hussein Cancer Center (KHCC), Amman, Jordan.
  • Matalka I; Department of Medicine, King Hussein Cancer Center (KHCC), Amman, Jordan.
  • Abdel Rahman Z; Nuclear Medicine and Diagnostic Section, Division of Human Health, International Atomic Energy Agency (IAEA), Vienna, Austria.
  • Fanti S; Department of Pathology, King Hussein Cancer Center (KHCC), Amman, Jordan.
Front Immunol ; 15: 1424269, 2024.
Article en En | MEDLINE | ID: mdl-39286245
ABSTRACT

Background:

Chimeric antigen receptor (CAR) T-cell therapy has attracted considerable attention since its recent endorsement by the Food and Drug Administration, as it has emerged as a promising immunotherapeutic modality within the landscape of oncology. This study explores the prognostic utility of [18F]Fluorodeoxyglucose positron emission tomography ([18F]FDG PET) in lymphoma patients undergoing CAR T-cell therapy. Through meta-analysis, pooled hazard ratio (HR) values were calculated for specific PET metrics in this context.

Methods:

PubMed, Scopus, and Ovid databases were explored to search for relevant topics. Dataset retrieval from inception until March 12, 2024, was carried out. The primary endpoints were impact of specific PET metrics on overall survival (OS) and progression-free survival (PFS) before and after treatment. Data from the studies were extracted for a meta-analysis using Stata 17.0.

Results:

Out of 27 studies identified for systematic review, 15 met the criteria for meta-analysis. Baseline OS analysis showed that total metabolic tumor volume (TMTV) had the highest HR of 2.66 (95% CI 1.52-4.66), followed by Total-body total lesion glycolysis (TTLG) at 2.45 (95% CI 0.98-6.08), and maximum standardized uptake values (SUVmax) at 1.30 (95% CI 0.77-2.19). TMTV and TTLG were statistically significant (p < 0.0001), whereas SUVmax was not (p = 0.33). For PFS, TMTV again showed the highest HR at 2.65 (95% CI 1.63-4.30), with TTLG at 2.35 (95% CI 1.40-3.93), and SUVmax at 1.48 (95% CI 1.08-2.04), all statistically significant (p ≤ 0.01). The ΔSUVmax was a significant predictor for PFS with an HR of 2.05 (95% CI 1.13-3.69, p = 0.015).

Conclusion:

[18F]FDG PET parameters are valuable prognostic tools for predicting outcome of lymphoma patients undergoing CAR T-cell therapy.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Fluorodesoxiglucosa F18 / Tomografía de Emisión de Positrones / Linfoma Límite: Humans Idioma: En Revista: Front Immunol Año: 2024 Tipo del documento: Article País de afiliación: Jordania Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunoterapia Adoptiva / Fluorodesoxiglucosa F18 / Tomografía de Emisión de Positrones / Linfoma Límite: Humans Idioma: En Revista: Front Immunol Año: 2024 Tipo del documento: Article País de afiliación: Jordania Pais de publicación: Suiza